Asset sale Announced

Grünenthal acquisition of Stivarga (regorafenib)

€375m consideration

Announced 21 Sep 2026

Advisers

Stivarga (regorafenib)

Target

Not disclosed

Grünenthal

Acquirer

Target
Stivarga (regorafenib)
Acquirer
Grünenthal
Seller
Bayer AG
Buyer based in
Germany
Seller based in
Germany
Sector
Pharma
Tags
Pharma, Oncology

Similar deals

All pharma deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.